Newsroom

News Releases

Mallinckrodt Announces Clinical and Healthcare Economics Research Study Data Presented and Published in Fourth Quarter Fiscal 2015

ST. LOUIS, October 6, 2015 -- Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced the following study data was presented on its
H.P. Acthar® Gel (repository corticotropin injection) product in the fourth quarter of fiscal 2015. Links shown provide access to each abstract or article.

Abstracts

Congress

Title

Link to Abstract

World Congress on Inflammation August 8-12, 2015

Healthcare Resource Use and Costs of Adrenocorticotropic Hormone in Relapses of Multiple Sclerosis

http://inflammation2015.org/PDFS/c 7/c72aac0c-2d9c-42b5-9095- 35e7438c2e57.pdf

World Congress on Inflammation August 8-12, 2015

Economic Consequences of Early versus Late use of Adrenocorticotropic Hormone Therapy in Infantile Spasms

http://inflammation2015.org/PDFS/2 c/2ce6b149-8ae6-438c-bc3d- 6b7efc76dd78.pdf

11th International Congress on Systemic Lupus Erythematosus
September 2-6, 2015

A Single-Site, Investigator-Initiated, Open- Label Trial of the Adrenocorticotropic Hormone Analog H.P. Acthar Gel (Repository Corticotropin Injection) Among Subjects with Active Systemic Lupus Erythematosus

http://www.abstractsonline.com/Pla n/ViewAbstract.aspx?sKey=f98f41a 1-4a98-4598-bccb-
7559fcde0686&cKey=b6a5a4a7- d2cf-441a-9cb3- ff1086065c17&mKey=c30c301e- 5776-46e1-8965-dafc9d5b8a04

11th International Congress on Systemic Lupus Erythematosus
September 2-6, 2015

H.P. Acthar Gel (Acthar) Attenuates Disease Activity in Patients With Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids

http://www.abstractsonline.com/Pla n/ViewAbstract.aspx?sKey=f98f41a 1-4a98-4598-bccb-
7559fcde0686&cKey=5d98baaa- 6343-4e23-a151-
658af882c3aa&mKey=c30c301e- 5776-46e1-8965-dafc9d5b8a04

11th International Congress on Systemic Lupus Erythematosus
September 2-6, 2015

Plasma Soluble Vascular Adhesion Molecule-1 (sVCAM-1) as an Exploratory Marker of Response to Therapy in Patients with Persistently Active Systemic Lupus Erythematosus (SLE)

http://www.abstractsonline.com/Pla n/ViewAbstract.aspx?sKey=f98f41a 1-4a98-4598-bccb-
7559fcde0686&cKey=55ae9fbe- 7bba-4420-bf87- fc4336566998&mKey=c30c301e- 5776-46e1-8965-dafc9d5b8a04

European Society of Paediatric Nephrology
September 3-5, 2015

Historical Analysis of Adrenocorticotropic Hormone Therapy for Nephrotic Syndrome

http://rd.springer.com/article/10.100 7/s00467-015-3158-7
(abstract available for purchase only)

Journal Article

Journal

Title

Link to Article

Journal of Clinical Pharmacology September 2015

Pharmacodynamics and Tolerability of Repository Corticotropin Injection in Healthy Human Subjects: A Comparison With Intravenous Methylprednisolone

http://onlinelibrary.wiley.com/enhan ced/doi/10.1002/jcph.582

ABOUT MALLINCKRODT

Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

CONTACTS:

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO 314-654-6649
cole.lannum@mallinckrodt.com

Media
Rhonda Sciarra Communications Manager 314-654-8618
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Senior Vice President, Communications and Public Affairs 314-654-3318
meredith.fischer@mallinckrodt.com